Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Abstract Background Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical decision making in only a small minority of screened...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Erlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, Cecilie J. Sandberg, Swapnil Potdar, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2019-12-01
Edice:Clinical and Translational Medicine
Témata:
Glioblastoma
Recurrent glioblastoma
Glioblastoma stem cells
High-throughput drug screening
Drug sensitivity and resistance testing
Individualized medicine
On-line přístup:http://link.springer.com/article/10.1186/s40169-019-0253-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky